GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Hepatitis B overview

Hepatitis B, a viral infection affecting the liver, poses a significant global health challenge due to its prevalence and potential for serious complications. Transmitted through contact with infected blood or bodily fluids, including sexual contact or sharing needles, Hepatitis B can lead to chronic liver disease, liver cancer, and even death if left untreated. Vaccination programs have been instrumental in reducing its spread, yet millions worldwide still remain affected. Accessible screening, early diagnosis, and comprehensive treatment are pivotal in managing Hepatitis B, preventing its transmission, and improving patient outcomes. Public awareness campaigns and healthcare initiatives are vital in combating this silent yet formidable threat to public health.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.